Temporomandibular Joint (TMJ) Disorder
Customize your policy alerts
Sign up for all blue cross blue shield - kansas policy alerts
Know when blue cross blue shield - kansas releases new policies or updates existing guidance.
Monitor payer policy activity
This policy governs diagnostic testing and therapeutic interventions for suspected or confirmed temporomandibular joint disorder (TMJD) for Blue Cross Blue Shield of Kansas members.
No material clinical or coverage changes in this revision.
Coverage Criteria for TMJD Services
Medically Necessary Diagnostic Procedures
Covered when ALL of the following are met
Cephalograms and pantograms reviewed individually
Medically Necessary Nonsurgical Treatments
Covered when ALL of the following are met
Conservative interventions recommended prior to more invasive/permanent therapies
Experimental / Investigational Diagnostics and Treatments
Not covered/experimental when ANY of the following are used for diagnosis or treatment
Listed as experimental/investigational
Listed as experimental/investigational
Medically Necessary Surgical Treatments
Covered when ALL of the following are met
Failure of conservative therapy required prior to arthroscopy/open surgery; check member contract for benefit applicability
Diagnostic Test Coverage Criteria
Coverage stance relies on demonstration of clinical validity and clinical utility:
From 'Clinically Valid' definition
From 'Clinically Useful' definition
From 'Chain of Evidence' and Section Summary (eg, ultrasound, surface EMG, joint vibration analysis unsupported)
Therapy Coverage Criteria
Coverage for intraoral devices and other treatments is tied to evidence of efficacy compared to alternatives and adequate follow-up:
Clinical context: treatment intended for confirmed TMJD
Study selection criteria and reliance on systematic reviews/RCTs
Outcomes section: minimum follow-up to demonstrate efficacy
Evidence considerations for coverage of nonsurgical TMJD therapies
Evidence-informed considerations for nonsurgical TMJD therapies
Based on network meta-analysis and systematic reviews
See section summary and systematic reviews
Based on RCTs and systematic reviews noting transient or no sustained benefit
Outcomes and study selection sections
Surgical follow-up evidence requirement
Covered when ALL of the following are met
Minimum follow-up duration stated for surgical techniques
Nonsurgical therapies — evidence characterization
Evidence summary statements to inform coverage decisions
June et al (2011), Liu et al (2021), Park et al (2023)
Manfredini, Machado, Goiato reviews summarized
Li 2024, Xu 2023, Al-Hamed 2021 findings
Sit et al (2021) and related RCTs
Evidence-based coverage considerations
Interpretive criteria based on synthesized evidence from systematic reviews and RCTs:
Based on systematic reviews and network meta-analysis
Al-Moraissi et al and related reviews
Mixed results across Hu 2023 and Thorpe 2023
Al-Moraissi network meta-analysis findings
Reflects quality ratings and heterogeneity reported
Sequencing: Conservative first, escalate if failed
Coverage considerations based on guideline-recommended sequencing and evidence:
Conservative management prior to surgery
- Conservative modalities: Includes maxillomandibular appliances, behavior modification, physical therapy, injections (corticosteroids or botulinum toxin noted by society), and NSAIDs.
Examples of first-line modalities per guideline
Efficacy evidence summary
Evidence from systematic reviews and meta-analyses:
See Vos et al, Hu et al, Al-Moraissi network meta-analysis
Observational outcomes for arthroscopy
Observational evidence:
Subjective primary outcome and retrospective design
Services and procedures explicitly listed in the policy as experimental or investigational are excluded from coverage as not medically necessary. Examples called out in the policy include diagnostic tests such as electromyography (including surface EMG), kinesiography, thermography, neuromuscular junction testing, somatosensory testing, computerized mandibular scan, ultrasound imaging/sonogram, arthroscopy for purely diagnostic purposes, and joint vibration analysis, as well as nonsurgical treatments such as electrogalvanic stimulation, iontophoresis, biofeedback, ultrasound, devices to maintain joint range of motion, orthodontic services, dental restorations/prostheses, TENS/PENS, acupuncture, hyaluronic acid injections, platelet concentrates, dextrose prolotherapy, and botulinum toxin.
The diagnostic use of ultrasound, surface electromyography (EMG), or joint vibration analysis for TMJD is considered unsupported by the available evidence. The policy states current evidence is insufficient or imprecise to establish clinical validity and clinical utility for these tests, and they are listed among experimental/investigational diagnostic procedures.
Certain interventions have shown no sustained benefit or have higher adverse event rates in randomized trials and systematic reviews. For example, a single-dose intra-articular injection of methylprednisolone did not demonstrate significant benefit over saline and was associated with a higher rate of adverse events in an RCT; similarly, trial data for botulinum toxin type A show transient pain reduction at 1 month but no sustained benefit at 3 to 6 months and the overall quality of evidence is low. These findings support considering such interventions as investigational or requiring additional justification for coverage.
The evidence does not reliably support use of biofeedback, transcutaneous electrical nerve stimulation (TENS), or routine orthodontic services for treatment of TMJD. Systematic reviews and section summaries report insufficient or inconsistent data to demonstrate meaningful, durable benefit for these modalities, and they are listed among treatments considered experimental/investigational in the policy.
The policy highlights treatments for which intermediate-term evidence is lacking or only short-term benefits have been reported; these interventions may be considered unsupported for routine coverage without additional documentation. While the policy does not enumerate every such procedure in this section, it emphasizes that many therapies show low or very low quality evidence, substantial heterogeneity across trials, or only short-term effects, which may affect coverage decisions.
The BMJ Rapid Recommendations panel recommends against or conditionally recommends against several interventions for chronic TMJD. Recommendations include advising against irreversible occlusal splints and discectomy (strong recommendations) and conditional recommendations against arthrocentesis, corticosteroid injections, hyaluronic acid, botulinum toxin, reversible occlusal splints, and several other therapies. These guideline positions are noted in the policy as potentially informing noncoverage or exclusion decisions.
Diagnostic tests and treatments explicitly listed as experimental or investigational in the policy (for example, EMG, joint vibration analysis, ultrasound, TENS, acupuncture, hyaluronic acid, platelet concentrates, dextrose prolotherapy, botulinum toxin, and others) are identified as not medically necessary for routine diagnosis or treatment of TMJD unless convincing, documented evidence of clinical utility is provided.
Diagnostic application of ultrasound, surface EMG, or joint vibration analysis for TMJD is considered unsupported because current evidence does not reliably demonstrate sufficient diagnostic accuracy or clinical utility. The policy notes that indirect evidence on clinical utility depends on adequate demonstration of clinical validity, which is lacking for these modalities.
Use of botulinum toxin type A or single-dose intra-articular methylprednisolone for TMJD is supported only by low-quality or inconsistent evidence. Systematic reviews and RCTs report transient or non-sustained pain reductions and low-quality evidence overall, and the policy indicates these therapies may be considered investigational or not medically necessary without stronger, longer-term outcome data.
Evidence is insufficient to support reliable, durable benefit for biofeedback, TENS, or routine orthodontic services in the management of TMJD. The policy and section summaries conclude that available studies are limited in number, small in size, or report only immediate posttreatment effects, leading to uncertain conclusions about effectiveness.
This section does not explicitly label additional specific procedures as not medically necessary beyond those listed, but it emphasizes the generally low or very low quality of evidence for many interventions and the need for intermediate-term (≥6 months) or longer follow-up to establish durable benefit. Treatments lacking such evidence or showing only short-term effects may be unsupported for routine coverage without further justification.
The BMJ Rapid Recommendations panel’s positions—strong recommendations against some irreversible or high-risk interventions and conditional recommendations against a range of other therapies—are cited in the policy as influential guidance. Where the BMJ panel recommends against an intervention (for example, irreversible occlusal splints or discectomy), those recommendations may be used to inform coverage exclusions or denials under this policy.
Coding and Device Identifiers
| FDA product code KZM | Product code for muscle-monitoring devices cleared via 510(k) |
| K003287 | K7x Evaluation System (Myotronics) 510(k) number |
| K082927 | BioEMG III (Bio-Research Associates) 510(k) number |
| K113677 | GrindCare Measure (Medotech A/S) 510(k) number |
| K130158 | M-Scan (Bio-Research Associates) 510(k) number |
| K161716 | TEETHAN 2.0 (BTS S.P.A.) 510(k) number |
| K163448 | GrindCare System (Sunstar Suisse S.A.) 510(k) number |
| K192469 | Nox Sleep System (Nox Medical) 510(k) number |
| No codes listed |
Provider Actions, Prior Authorization, and Documentation
Presurgical imaging may require review
Presurgical imaging (CT, MRI) is generally reserved for presurgical evaluations and may require prior review or authorization. Verify member benefits and any applicable state/federal mandates before ordering advanced imaging and document the clinical indication and how imaging will affect surgical planning.
- CT/MRI commonly used for presurgical evaluation
- Document clinical indication and impact on surgical decision-making
- Verify member benefits prior to service
Prior authorization: sustained benefit and diagnosis
Prior authorization for nonsurgical therapies (eg, intraoral devices, appliances) and surgical procedures may require evidence of a confirmed TMJD diagnosis and documentation of sustained benefit. For intraoral devices, the literature supporting efficacy often requires at least 1 year of follow-up to demonstrate sustained benefit; requests should include prior conservative therapy attempts and objective outcome data.
- Confirmed TMJD diagnosis required
- Document prior conservative therapies and response
- Provide ≥1 year follow-up evidence for nonsurgical device efficacy
Prior authorization — surgical follow-up evidence
For surgical TMJ procedures, prior authorization pathways should expect evidence of diagnosis, prior conservative therapy attempts, and supporting clinical outcome data. Surgical claims or authorization requests should include at least intermediate-term follow-up (generally ≥6 months) demonstrating clinical benefit where indicated by the evidence base.
- Confirm diagnosis and document prior conservative therapy
- Include clinical outcome data with ≥6 months follow-up for surgical efficacy
Prior authorization — evidence of intermediate-term benefit
Consideration of intermediate-term benefit (≥6 months) from arthroscopy, arthrocentesis, and injectable therapies (eg, hyaluronic acid, corticosteroid) is supported by some systematic reviews and network meta-analyses. Authorization requests for these procedures should include outcome measures at or beyond 6 months when available.
- Arthroscopy/arthrocentesis may show benefit at ≥6 months
- Include ≥6 month outcome data when available for injections and minimally invasive procedures
Prior authorization guidance for surgical TMJ procedures
Guidance for prior authorization of surgical TMJ procedures aligns with guideline-based accepted options (eg, arthrocentesis, arthroscopy, condylotomy, arthrotomy/prosthetic joint replacement). Requests should document prior nonsurgical management, indications for surgery, and available outcome data supporting the chosen surgical approach.
- Accepted surgical options: arthrocentesis, arthroscopy, condylotomy, arthrotomy/prosthetic joint replacement
- Document indication, prior nonsurgical care, and outcomes supporting surgery
Prior authorization not specified
Some references and contexts in the source do not specify explicit prior authorization requirements. In such cases, follow plan-specific authorization rules and verify benefits and coverage details with BCBSKS.
- When prior authorization is not specified in references, verify plan requirements
- Follow member contract language and state/federal mandates
Follow-up requirement risk
Insufficient follow-up (eg, <6 months for surgical techniques or <1 year for nonsurgical device therapies) may not demonstrate durable efficacy. Requests lacking adequate intermediate- or long-term follow-up data may be at risk for denial or request for additional documentation.
- Risk of denial for insufficient follow-up data (<6 months for surgical, <1 year for nonsurgical devices)
- Provide intermediate- and long-term outcome measures when available
Nonsurgical treatment is recommended as first-line therapy
Clinical practice guidelines and specialty society statements recommend nonsurgical treatment as first-line therapy for symptomatic TMJD. Initial management should emphasize conservative, reversible, evidence-based modalities (eg, soft diet, rest, heat/ice, avoiding extreme jaw movement, NSAIDs, physical therapy, and intraoral appliances when appropriate). If adequate symptom relief is not achieved within 2–3 weeks, consider surgical consultation per guideline recommendations.
- Conservative measures recommended before invasive/permanent therapies
- Consider surgical consultation if symptoms persist after 2–3 weeks of appropriate conservative care
Step through conservative therapies
When considering intraoral appliances or other nonsurgical options, step through conservative therapies first (eg, medications, physical therapy, behavioral interventions). Use intraoral devices within the context of alternative nonsurgical interventions and as part of a stepwise care plan.
- Sequence care: conservative measures → adjunct nonsurgical therapies → devices/injections → surgical options
- Document failure or insufficiency of prior conservative measures
Step through established nonsurgical therapies first
Consider established nonsurgical therapies (manual therapy, CBT with biofeedback/relaxation, supervised jaw exercises, acupuncture, physical therapy, analgesics) before escalating to more invasive interventions. Evidence supports some of these modalities for pain reduction; the certainty of evidence for orthotics and other interventions varies.
- Prioritize evidence-based nonsurgical options: manual therapy, CBT, supervised exercises, acupuncture, physical therapy
- Document rationale for choosing intraoral devices versus alternative nonsurgical options
Stepwise consideration of nonsurgical alternatives
Consider nonsurgical alternatives (eg, intraoral appliances, physical therapy, acupuncture, HA injections) in a stepwise manner before surgical intervention. Capture objective baseline measures and demonstrate treatment response over time to support continued care or escalation.
- Use a stepwise approach: noninvasive → minimally invasive → surgical
- Collect baseline and follow-up measures to document response
Study design and reporting expectations
Reports of diagnostic studies and clinical outcome reports should describe the study population, include comparison with a credible reference standard when applicable, and report relevant diagnostic performance measures (sensitivity, specificity, predictive values) or clinical outcomes. For clinical studies, prefer prospective controlled designs (RCTs when feasible) and single-arm studies for long-term outcomes when necessary.
- Report population, reference standards, and diagnostic performance (sensitivity/specificity)
- Prefer RCTs for efficacy; prospective comparative studies when RCTs unavailable; single-arm for long-term safety/outcomes
Device-specific and outcome documentation
Documentation for device-based treatments should specify the type of intraoral device or splint, fabrication and adjustment details, baseline and follow-up pain measures (eg, VAS), and objective functional measures (eg, maximal mouth opening). Specify whether different devices are used day versus night and include adherence information when available.
- Specify device type, fabrication, insertion, and adjustment dates
- Include baseline and follow-up VAS pain scores and maximal mouth opening measures
- Document device usage/adherence
Evidence and follow-up documentation
Selection of clinical evidence for authorization and coverage decisions prioritizes RCTs and comparative prospective studies for efficacy and single-arm studies with longer follow-up for long-term outcomes. Documentation supporting requests should reference comparative evidence and available follow-up durations.
- Prioritize RCTs and comparative prospective studies to demonstrate efficacy
- Use single-arm or registry data to document long-term outcomes and adverse events
Conservative therapy first
Conservative, reversible therapies (soft diet, rest, heat/ice, NSAIDs, physical therapy, splints) are recommended before considering invasive or permanent interventions. Document trials of these measures and the clinical response prior to authorization of more invasive therapies.
- Document trials of conservative measures and response
- Emphasize reversible/evidence-based modalities first
Step through conservative therapies
When reviewing requests, ensure the care plan steps through conservative therapies and documents reason(s) for escalation (eg, inadequate symptom relief, functional impairment). Prior authorization may require demonstration that alternatives were considered and tried.
- Demonstrate trial and failure or insufficiency of conservative measures
- Provide rationale for selecting next-step interventions
References only
References provided in this section are bibliographic support for clinical and policy statements and do not, by themselves, establish authorization criteria. Use the cited literature to inform clinical rationale and to support documentation submitted with authorization requests.
- References list (see policy references) supports clinical rationale
- Reference lists do not substitute for plan-specific authorization rules
Background and Scope
Temporomandibular joint disorder (TMJD) encompasses a group of conditions affecting the temporomandibular joint and related structures, commonly presenting with jaw pain, joint sounds (clicking), limited mouth opening, and associated regional symptoms. Etiology is multifactorial and management typically begins with conservative, reversible therapies; imaging and invasive procedures are generally reserved for confirmed diagnoses, persistent symptoms, or presurgical planning.
Definitions and Key Terms
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.